Literature DB >> 26957665

Mycobacterium Tuberculosis Infection, Immigration Status, and Diagnostic Discordance: A Comparison of Tuberculin Skin Test and QuantiFERON-TB Gold In-Tube Test Among Immigrants to the U.S.

Fernando A Wilson1, Thaddeus L Miller2, Jim P Stimpson3.   

Abstract

OBJECTIVE: We used a recent source of nationally representative population data on tuberculosis (TB) infection to characterize concordance between the tuberculin skin test (TST) and the QuantiFERON-TB Gold In-Tube (QFT-GIT) blood test for immigrants in the United States.
METHODS: We used TB screening data from the 2011-2012 National Health and Nutrition Examination Survey to examine concordance between the TST and QFT-GIT--an interferon-gamma release assay (IGRA) blood test--for 7,097 U.S. natives, naturalized citizens, and noncitizens.
RESULTS: Consistent with prior findings, one in five immigrants in the survey was identified with latent TB infection (LTBI), a rate 14 times higher than for U.S. natives. We also found higher rates of discordant TST/IGRA results among immigrants than among U.S. natives. Unadjusted discordance between TST and IGRA was 3% among U.S. natives (weighted N=5,684,274 of 191,179,213) but ranged up to 19% for noncitizens (weighted N=3,722,960 of 19,377,147). Adjusting for age, sex, and race/ethnicity, noncitizens had more than nine times the odds of having a positive TST result but negative QFT-GIT result compared with U.S. natives.
CONCLUSIONS: Our findings suggest that whether and how either of these tests should be deployed is highly context sensitive. Significant discordance in test results when used among immigrants raises the possibility of missed opportunities for harm reduction in this already at-risk population. However, we found little distinction between the tests in terms of diagnostic outcome when used in a U.S. native population, suggesting little benefit to the adoption and use of the QFT-GIT test in place of TST on the basis of test performance alone for this population.

Entities:  

Mesh:

Year:  2016        PMID: 26957665      PMCID: PMC4765979          DOI: 10.1177/003335491613100214

Source DB:  PubMed          Journal:  Public Health Rep        ISSN: 0033-3549            Impact factor:   2.792


  30 in total

1.  Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study.

Authors:  Giovanni Ferrara; Monica Losi; Roberto D'Amico; Pietro Roversi; Roberto Piro; Marisa Meacci; Barbara Meccugni; Ilaria Marchetti Dori; Alessandro Andreani; Barbara Maria Bergamini; Cristina Mussini; Fabio Rumpianesi; Leonardo M Fabbri; Luca Richeldi
Journal:  Lancet       Date:  2006-04-22       Impact factor: 79.321

2.  Domestic returns from investment in the control of tuberculosis in other countries.

Authors:  Kevin Schwartzman; Olivia Oxlade; R Graham Barr; Franque Grimard; Ivelisse Acosta; Jeannette Baez; Elizabeth Ferreira; Ricardo Elías Melgen; Willy Morose; Arturo Cruz Salgado; Vary Jacquet; Susan Maloney; Kayla Laserson; Ariel Pablos Mendez; Dick Menzies
Journal:  N Engl J Med       Date:  2005-09-08       Impact factor: 91.245

Review 3.  Tuberculosis.

Authors:  Alimuddin Zumla; Mario Raviglione; Richard Hafner; C Fordham von Reyn
Journal:  N Engl J Med       Date:  2013-02-21       Impact factor: 91.245

4.  Predictors of discordant tuberculin skin test and QuantiFERON®-TB Gold In-Tube results in various high-risk groups.

Authors:  P Weinfurter; H M Blumberg; G Goldbaum; R Royce; J Pang; J Tapia; J Bethel; G H Mazurek; S Toney; R Albalak
Journal:  Int J Tuberc Lung Dis       Date:  2011-08       Impact factor: 2.373

5.  Cost-effectiveness of QuantiFERON-TB test vs. tuberculin skin test in the diagnosis of latent tuberculosis infection.

Authors:  S Deuffic-Burban; K Atsou; N Viget; H Melliez; E Bouvet; Y Yazdanpanah
Journal:  Int J Tuberc Lung Dis       Date:  2010-04       Impact factor: 2.373

6.  Pulmonary impairment after tuberculosis.

Authors:  Jotam G Pasipanodya; Thaddeus L Miller; Mauricio Vecino; Guadalupe Munguia; Robert Garmon; Sejong Bae; Gerry Drewyer; Stephen E Weis
Journal:  Chest       Date:  2007-03-30       Impact factor: 9.410

7.  Social networks and the spread of infectious diseases: the AIDS example.

Authors:  A S Klovdahl
Journal:  Soc Sci Med       Date:  1985       Impact factor: 4.634

8.  Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society.

Authors: 
Journal:  MMWR Recomm Rep       Date:  2000-06-09

9.  Estimating the burden of tuberculosis among foreign-born persons acquired prior to entering the U.S., 2005-2009.

Authors:  Philip M Ricks; Kevin P Cain; John E Oeltmann; J Steve Kammerer; Patrick K Moonan
Journal:  PLoS One       Date:  2011-11-29       Impact factor: 3.240

10.  Feasibility, acceptability, and cost of tuberculosis testing by whole-blood interferon-gamma assay.

Authors:  Puneet Kumar Dewan; Jennifer Grinsdale; Sally Liska; Ernest Wong; Robert Fallstad; L Masae Kawamura
Journal:  BMC Infect Dis       Date:  2006-03-15       Impact factor: 3.090

View more
  2 in total

1.  Challenges in LTBI care in the United States identified using a nationwide TB medical consultation database.

Authors:  N T Agathis; R Bhavaraju; V Shah; L Chen; C A Haley; N D Goswami; A Patrawalla
Journal:  Public Health Action       Date:  2021-09-21

2.  Pulmonary immune responses to Mycobacterium tuberculosis in exposed individuals.

Authors:  Christian Herzmann; Martin Ernst; Christoph Lange; Steffen Stenger; Stefan H E Kaufmann; Norbert Reiling; Tom Schaberg; Lize van der Merwe; Jeroen Maertzdorf
Journal:  PLoS One       Date:  2017-11-10       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.